Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.54 |
| ▸ | CNR2 | P34972 | 7/20 | 0.54 |
| ▸ | BID | P55957 | 3/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.51 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.51 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | EP300 | Q09472 | 2/20 | 0.51 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.51 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.51 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134439 | 0.87 | PPARG (0.57) | CNR1CNR2BIDMCL1KAT8 | |
| SCHEMBL1836104 | 0.87 | PPARA (0.50) | CNR1CNR2BIDMCL1KAT8 | |
| SCHEMBL1837528 | 0.87 | PPARA (0.50) | CNR1CNR2BIDMCL1KAT8 | |
| SCHEMBL1836934 | 0.87 | PPARA (0.50) | CNR1CNR2BIDMCL1KAT8 | |
| SCHEMBL1841439 | 0.87 | PPARA (0.50) | CNR1CNR2BIDMCL1KAT8 | |
| SCHEMBL1835054 | 0.87 | PPARA (0.50) | CNR1CNR2BIDMCL1KAT8 | |
| SCHEMBL1835875 | 0.85 | PPARA (0.59) | BIDMCL1KAT8PPARABCL2L1 | |
| SCHEMBL1840783 | 0.85 | PPARA (0.59) | BIDMCL1KAT8PPARABCL2L1 | |
| SCHEMBL1839755 | 0.85 | PPARA (0.59) | BIDMCL1KAT8PPARABCL2L1 | |
| SCHEMBL1833200 | 0.85 | PPARA (0.56) | BIDMCL1KAT8PPARABCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152577-A1 | Pharmaceutical Composition of Ethidium Bromide and Use in Treating Cancer | SHANGHAI INSTITUTE FOR ENDOCRINE AND METABOLIC DISEASES (CN) | 2025-05-15 | — | — | US | disclosed |
| EP-4458359-A1 | PHARMACEUTICAL COMPOSITION OF ETHIDIUM BROMIDE, AND USE THEREOF IN TREATING CANCER | Ruijin Hospital, Shanghai Jiaotong University School of Medicine (CN) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023207982-A1 | PHARMACEUTICAL COMPOSITION OF ETHIDIUM BROMIDE, AND USE THEREOF IN TREATING CANCER | 上海交通大学医学院附属瑞金医院 | 2023-11-02 | — | — | WO | disclosed |
| CN-115884772-A | SMARCA4 inhibition for the treatment of cancer | EPIZYME股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-110088099-B | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof | EPIZYME股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-114929231-A | Use of imidazopyrimidine or imidazotriazine compounds for preventing, alleviating or treating developmental disabilities | 爱思开生物制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-114929230-A | Use of imidazopyrimidine or imidazotriazine compounds for the prevention, alleviation or treatment of cognitive disorders or for improving cognitive function | 爱思开生物制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-114929688-A | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114641466-A | Sulfonylurea derivatives and use thereof | 诺瑟拉有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114641314-A | Method for treating or preventing chronic kidney disease | 日本烟草产业株式会社 | 2022-06-17 | — | — | CN | disclosed |
| CN-111315371-A | Methods of treating or preventing hematologic disorders using EHMT2 inhibitors | 埃皮兹姆公司 | 2020-06-19 | — | — | CN | disclosed |
| CN-111212839-A | Pyrazolopyrimidinone compounds and uses thereof | 艾杜罗生物科技公司 | 2020-05-29 | — | — | CN | disclosed |
| CN-111201021-A | Chroman monocyclic β -lactams for use in the treatment of bacterial infections | 默沙东公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-111201017-A | Methods for preparing deuterium-enriched N-acetylcysteine amide (D-NACA) and (2R,2R ') -3,3' -disulfanediylbis (2-acetamidopropionamide) (DINACA) and for treating diseases involving oxidative stress using D-NACA and DINACA | 纳崔泰制药有限公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-111065414-A | Combinations for treating cancer | 埃沃尔科学有限责任公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-111050772-A | Isotopically labelled bile acid derivatives | 英特塞普特医药品公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-110898067-A | Method of cancer treatment | EPIZYME股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-110621316-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2019-12-27 | — | — | CN | disclosed |
| CN-105008335-B | Method for synthesizing thyroid hormone analogue and its polymorph | 马德里加尔制药公司 | 2018-12-21 | — | — | CN | disclosed |
| US-8926997-B1 | Polymeric biocidal salts | NEVADA NATURALS INC. | 2015-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152577-A1 | Pharmaceutical Composition of Ethidium Bromide and Use in Treating Cancer | ABCB1, BAX, BCL2 | CNR1 1898/4885CNR2 1605/4885BID 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.